Announcements Trials
Browse Landscape

Phase

Phase 2 48Phase 1 18Phase 1/2 10Phase 3 9Phase NA 7Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 6Completed 4Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Saline Solution 6Fentanyl 6Sodium Chloride 5Letrozole 5Dexamethasone 5Pregabalin 4Ketamine 4Goserelin 4Gemcitabine 4Bevacizumab 4Tranexamic Acid 3Photochemotherapy 3Pemetrexed 3Paclitaxel 3Metformin 3Leuprolide 3Docetaxel 3Cyclophosphamide 3Carboplatin 3Capecitabine 3Acetaminophen 3ulipristal acetate 2sodium glycididazole 2nilotinib 2liposomal doxorubicin 2human papillomavirus vaccine, L1 type 16, 18 2flurbiprofen axetil 2fludarabine 2fluciclovine F-18 2epoetin beta 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Terminated × Sorafenib × Clear all
NCT01849588 2017-04-19

HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Massachusetts General Hospital

Phase 4 Terminated
3 enrolled 5 charts
Gastrointestinal

Liver Neoplasms

NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡